{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:50:46Z","timestamp":1794873046291,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR179 (TP15\/TP18)"],"award-info":[{"award-number":["TRR179 (TP15\/TP18)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis delta virus (HDV) depends on the helper function of hepatitis B virus (HBV), which provides the envelope proteins for progeny virus secretion. Current infection-competent cell culture models do not support assembly and secretion of HDV. By stably transducing HepG2 cells with genes encoding the NTCP-receptor and the HBV envelope proteins we produce a cell line (HepNB2.7) that allows continuous secretion of infectious progeny HDV following primary infection. Evaluation of antiviral drugs shows that the entry inhibitor Myrcludex B (IC<jats:sub>50<\/jats:sub>: 1.4\u2009nM) and interferon-\u03b1 (IC<jats:sub>50<\/jats:sub>: 28\u2009IU\/ml, but max. 60\u201380% inhibition) interfere with primary infection. Lonafarnib inhibits virus secretion (IC<jats:sub>50<\/jats:sub>: 36\u2009nM) but leads to a substantial intracellular accumulation of large hepatitis delta antigen and replicative intermediates, accompanied by the induction of innate immune responses. This work provides a cell line that supports the complete HDV replication cycle and presents a convenient tool for antiviral drug evaluation.<\/jats:p>","DOI":"10.1038\/s41467-019-10211-2","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T10:04:48Z","timestamp":1558519488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation"],"prefix":"10.1038","volume":"10","author":[{"given":"Florian A.","family":"Lempp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rieble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-0342","authenticated-orcid":false,"given":"Lea","family":"Nussbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"10211_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","volume":"13","author":"FA Lempp","year":"2016","unstructured":"Lempp, F. A., Ni, Y. & Urban, S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat. Rev. Gastroenterol. Hepatol. 13, 580\u2013589 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10211_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.antiviral.2015.08.009","volume":"122","author":"D Alfaiate","year":"2015","unstructured":"Alfaiate, D., Deny, P. & Durantel, D. Hepatitis delta virus: from biological and medical aspects to current and investigational therapeutic options. Antivir. Res. 122, 112\u2013129 (2015).","journal-title":"Antivir. Res."},{"key":"10211_CR3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/jvi.63.5.1945-1950.1989","volume":"63","author":"MYP Kuo","year":"1989","unstructured":"Kuo, M. Y. P., Chao, M. & Taylor, J. Initiation of replication of the human hepatitis-delta virus genome from cloned DNA\u2014role of delta-antigen. J. Virol. 63, 1945\u20131950 (1989).","journal-title":"J. Virol."},{"key":"10211_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.1598578","volume":"256","author":"JS Glenn","year":"1992","unstructured":"Glenn, J. S., Watson, J. A., Havel, C. M. & White, J. M. Identification of a prenylation site in delta virus large antigen. Science 256, 1331\u20131333 (1992).","journal-title":"Science"},{"key":"10211_CR5","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1128\/jvi.67.12.7659-7662.1993","volume":"67","author":"SB Hwang","year":"1993","unstructured":"Hwang, S. B. & Lai, M. M. Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen. J. Virol. 67, 7659\u20137662 (1993).","journal-title":"J. Virol."},{"key":"10211_CR6","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1128\/JVI.03540-12","volume":"87","author":"H Yan","year":"2013","unstructured":"Yan, H. et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J. Virol. 87, 7977\u20137991 (2013).","journal-title":"J. Virol."},{"key":"10211_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jhep.2015.10.030","volume":"64","author":"FA Lempp","year":"2016","unstructured":"Lempp, F. A. et al. Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor. J. Hepatol. 64, 556\u2013564 (2016).","journal-title":"J. Hepatol."},{"key":"10211_CR8","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 1, e00049 (2012).","journal-title":"elife"},{"issue":"4","key":"10211_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v9040075","volume":"9","author":"Thomas Tu","year":"2017","unstructured":"Tu, T., Budzinska, M. A., Shackel, N. A. & Urban, S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses 9, 75 (2017). https:\/\/doi.org\/10.3390\/v9040075","journal-title":"Viruses"},{"issue":"11","key":"10211_CR10","doi-asserted-by":"publisher","first-page":"e02007","DOI":"10.1128\/JVI.02007-17","volume":"92","author":"Thomas Tu","year":"2018","unstructured":"Tu, T., Budzinska, M. A., Vondran, F. W. R., Shackel, N. A. & Urban, S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles. J. Virol. https:\/\/doi.org\/10.1128\/jvi.02007-17 (2018).","journal-title":"Journal of Virology"},{"key":"10211_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jhep.2013.11.010","volume":"60","author":"K Giersch","year":"2014","unstructured":"Giersch, K. et al. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. J. Hepatol. 60, 538\u2013544 (2014).","journal-title":"J. Hepatol."},{"key":"10211_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2016.10.006","volume":"136","author":"D Alfaiate","year":"2016","unstructured":"Alfaiate, D. et al. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. Antivir. Res. 136, 19\u201331 (2016).","journal-title":"Antivir. Res."},{"key":"10211_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jhep.2015.03.011","volume":"63","author":"K Giersch","year":"2015","unstructured":"Giersch, K. et al. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. J. Hepatol. 63, 346\u2013353 (2015).","journal-title":"J. Hepatol."},{"key":"10211_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2018.02.021","volume":"69","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z. et al. Hepatitis D virus replication is sensed by MDA5 and induces IFN-beta\/lambda responses in hepatocytes. J. Hepatol. 69, 25\u201335 (2018).","journal-title":"J. Hepatol."},{"key":"10211_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/hep.27585","volume":"61","author":"M Rizzetto","year":"2015","unstructured":"Rizzetto, M. & Smedile, A. Pegylated interferon therapy of chronic hepatitis D: in need of revision. Hepatology 61, 1109\u20131111 (2015).","journal-title":"Hepatology"},{"key":"10211_CR16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh, C. et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect. Dis. 15, 1167\u20131174 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"10211_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/hep.29658","volume":"67","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin, C. et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology 67, 1224\u20131236 (2018).","journal-title":"Hepatology"},{"issue":"3","key":"10211_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"Pavel Bogomolov","year":"2016","unstructured":"Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016 (2016).","journal-title":"Journal of Hepatology"},{"key":"10211_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","volume":"58","author":"T Volz","year":"2013","unstructured":"Volz, T. et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol. 58, 861\u2013867 (2013).","journal-title":"J. Hepatol."},{"key":"10211_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/hep.28013","volume":"63","author":"ER Verrier","year":"2016","unstructured":"Verrier, E. R. et al. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology 63, 35\u201348 (2016).","journal-title":"Hepatology"},{"key":"10211_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","volume":"146","author":"Y Ni","year":"2014","unstructured":"Ni, Y. et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070\u20131083 (2014).","journal-title":"Gastroenterology"},{"key":"10211_CR22","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1128\/JVI.77.9.5519-5523.2003","volume":"77","author":"C Sureau","year":"2003","unstructured":"Sureau, C., Fournier-Wirth, C. & Maurel, P. Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virus. J. Virol. 77, 5519\u20135523 (2003).","journal-title":"J. Virol."},{"key":"10211_CR23","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/jvi.68.6.4063-4066.1994","volume":"68","author":"C Sureau","year":"1994","unstructured":"Sureau, C., Guerra, B. & Lee, H. The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus. J. Virol. 68, 4063\u20134066 (1994).","journal-title":"J. Virol."},{"key":"10211_CR24","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","volume":"41","author":"SK Ladner","year":"1997","unstructured":"Ladner, S. K. et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41, 1715\u20131720 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"10211_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.antiviral.2017.02.008","volume":"141","author":"B Buchmann","year":"2017","unstructured":"Buchmann, B. et al. A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. Antivir. Res. 141, 116\u2013123 (2017).","journal-title":"Antivir. Res."},{"key":"10211_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jviromet.2018.07.010","volume":"260","author":"ME Quintana","year":"2018","unstructured":"Quintana, M. E. et al. A direct high-throughput in Cell-ELISA for measuring infectivity of cytopathic and non-cytopathic bovine viral diarrhoea virus strains applied to the assessment of antiviral activity. J. Virol. Methods 260, 75\u201381 (2018).","journal-title":"J. Virol. Methods"},{"key":"10211_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jviromet.2013.06.007","volume":"193","author":"KB Spurgers","year":"2013","unstructured":"Spurgers, K. B. et al. Validation of a cell-based ELISA as a screening tool identifying anti-alphavirus small-molecule inhibitors. J. Virol. Methods 193, 226\u2013231 (2013).","journal-title":"J. Virol. Methods"},{"key":"10211_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","volume":"147","author":"S Urban","year":"2014","unstructured":"Urban, S., Bartenschlager, R., Kubitz, R. & Zoulim, F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147, 48\u201364 (2014).","journal-title":"Gastroenterology"},{"key":"10211_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1128\/JVI.75.1.143-150.2001","volume":"75","author":"KM Breiner","year":"2001","unstructured":"Breiner, K. M., Urban, S., Glass, B. & Schaller, H. Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes. J. Virol. 75, 143\u2013150 (2001).","journal-title":"J. Virol."},{"key":"10211_CR30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/0092-8674(94)90360-3","volume":"76","author":"C Aiken","year":"1994","unstructured":"Aiken, C., Konner, J., Landau, N. R., Lenburg, M. E. & Trono, D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76, 853\u2013864 (1994).","journal-title":"Cell"},{"key":"10211_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jhep.2010.10.019","volume":"55","author":"CM Bremer","year":"2011","unstructured":"Bremer, C. M. et al. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J. Hepatol. 55, 29\u201337 (2011).","journal-title":"J. Hepatol."},{"key":"10211_CR32","doi-asserted-by":"publisher","first-page":"7925","DOI":"10.1128\/JVI.78.15.7925-7937.2004","volume":"78","author":"KA Walters","year":"2004","unstructured":"Walters, K. A., Joyce, M. A., Addison, W. R., Fischer, K. P. & Tyrrell, D. L. Superinfection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen. J. Virol. 78, 7925\u20137937 (2004).","journal-title":"J. Virol."},{"key":"10211_CR33","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1128\/JVI.78.15.8120-8134.2004","volume":"78","author":"S Sato","year":"2004","unstructured":"Sato, S., Cornillez-Ty, C. & Lazinski, D. W. By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber\/W editing and its own expression. J. Virol. 78, 8120\u20138134 (2004).","journal-title":"J. Virol."},{"issue":"1","key":"10211_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/gutjnl-2017-314713","volume":"68","author":"Katja Giersch","year":"2017","unstructured":"Giersch, K. et al. Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. Gut https:\/\/doi.org\/10.1136\/gutjnl-2017-314713 (2017).","journal-title":"Gut"},{"key":"10211_CR35","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","volume":"68","author":"H Wedemeyer","year":"2018","unstructured":"Wedemeyer, H. et al. GS-005\u2014Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection. J. Hepatol. 68, S3 (2018).","journal-title":"J. Hepatol."},{"key":"10211_CR36","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/1873-3468.12202","volume":"590","author":"Z Zhang","year":"2016","unstructured":"Zhang, Z., Zehnder, B., Damrau, C. & Urban, S. Visualization of hepatitis B virus entry\u2014novel tools and approaches to directly follow virus entry into hepatocytes. FEBS Lett. 590, 1915\u20131926 (2016).","journal-title":"FEBS Lett."},{"key":"10211_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nmeth.1638","volume":"8","author":"X Yang","year":"2011","unstructured":"Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nat. methods 8, 659\u2013661 (2011).","journal-title":"Nat. methods"},{"key":"10211_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jviromet.2011.11.001","volume":"179","author":"RB Ferns","year":"2012","unstructured":"Ferns, R. B., Nastouli, E. & Garson, J. A. Quantitation of hepatitis delta virus using a single-step internally controlled real-time RT-qPCR and a full-length genomic RNA calibration standard. J. Virol. Methods 179, 189\u2013194 (2012).","journal-title":"J. Virol. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10211-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10211-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10211-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T23:46:12Z","timestamp":1671234372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10211-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["10211"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-10211-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"27 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.U. is a co-applicant and co-inventor on patents protecting Myrcludex B as an HBV\/HDV entry inhibitor. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2265"}}